the drug-resistance mutations of Trks have already emerged, which calls for new-generation Trks inhibitors. Herein, we report the structural optimization and structure–activity relationship studies of 6,6-dimethyl-4-(phenylamino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one derivatives as a new class of pan-Trk inhibitors. The prioritized compound 11g exhibited low nanomolar IC50 values against TrkA, TrkB
原肌球蛋白受体激酶(TrkA、TrkB 和 TrkC)是多种癌症的有吸引力的治疗靶点。两种第一代小分子 Trks
抑制剂 larotrectinib 和 entrectinib 刚刚被批准用于临床。然而,Trks的耐药突变已经出现,这就需要新一代的Trks
抑制剂。在此,我们报告了 6,6-dimethyl-4-(phenylamino)-6 H -pyrimido[5,4- b ][1,4]oxazin-7(8 H )-的结构优化和构效关系研究一种衍
生物作为一类新的泛 Trk
抑制剂。优先化合物11g表现出低纳摩尔 IC 50对 TrkA、TrkB 和 TrkC 以及各种耐药突变体的值。它还显示出良好的激酶选择性。11g在完整细胞中表现出优异的体外抗肿瘤活性并强烈抑制 Trk 介导的信号通路。在体内研究中,化合物11g在 BaF3-TEL-TrkA 和 BaF3-TEL-TrkC G623